About ImmunoSCAPE
ImmunoSCAPE is a company based in Singapore (Singapore) founded in 2016.. ImmunoSCAPE has raised $39 million across 4 funding rounds from investors including Amgen, Anzu Partners and EDBI. ImmunoSCAPE offers products and services including TCR-based Therapeutics, Deep Immunomics Platform, and Machine Learning Platform. ImmunoSCAPE operates in a competitive market with competitors including Reaction Biology, PhenoVista, Discovery Biomed, BCI Pharma and ICE Bioscience, among others.
- Headquarter Singapore, Singapore
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immunoscape Pte Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$39 M (USD)
in 4 rounds
-
Latest Funding Round
$14 M (USD), Series B
Sep 20, 2022
-
Investors
Amgen
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImmunoSCAPE
ImmunoSCAPE offers a comprehensive portfolio of products and services, including TCR-based Therapeutics, Deep Immunomics Platform, and Machine Learning Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops novel T cell receptor therapies targeting solid tumors.
Platform for discovering TCRs using immunomics and machine learning.
Applies AI to identify and optimize TCR-based therapeutic candidates.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of ImmunoSCAPE
ImmunoSCAPE has successfully raised a total of $39M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $14 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $14.0M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Series B - ImmunoSCAPE | Valuation | Anzu Partners | |
| Apr, 2021 | Amount | Series B - ImmunoSCAPE | Valuation | Anzu Partners , UTEC | |
| Aug, 2020 | Amount | Series A - ImmunoSCAPE | Valuation | Anzu Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ImmunoSCAPE
ImmunoSCAPE has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Anzu Partners and EDBI. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in industrial and life sciences technology companies.
|
Founded Year | Domain | Location | |
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Founded Year | Domain | Location | |
|
Seed and Early stage VC firm investing in Japan
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ImmunoSCAPE
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ImmunoSCAPE
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immunoscape Comparisons
Competitors of ImmunoSCAPE
ImmunoSCAPE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Reaction Biology, PhenoVista, Discovery Biomed, BCI Pharma and ICE Bioscience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
|
|
| domain | founded_year | HQ Location |
A CRO that provides phenotypic assay development and screening services.
|
|
| domain | founded_year | HQ Location |
Custom human cell engineering and drug discovery services are provided.
|
|
| domain | founded_year | HQ Location |
Contract research services in cancer and neuroinflammation are offered.
|
|
| domain | founded_year | HQ Location |
Specialised CRO offering a range of screening platforms for cardiac safety testing, ion channel profiling and in vitro HTS screening
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immunoscape
Frequently Asked Questions about ImmunoSCAPE
When was ImmunoSCAPE founded?
ImmunoSCAPE was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Where is ImmunoSCAPE located?
ImmunoSCAPE is headquartered in Singapore, Singapore.
Is ImmunoSCAPE a funded company?
ImmunoSCAPE is a funded company, having raised a total of $39M across 4 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on Jan 22, 2020.
What does ImmunoSCAPE do?
ImmunoSCAPE was founded in 2016 in Singapore as a spin-off from Dr. Evan Newells lab at ASTARs Singapore Immunology Network. Services focus on biomarker and target identification in immunology, using mass cytometry for immune cell and T-cell analysis in oncology and infectious diseases. Operations involve antigen discovery, cell profiling, and data tools to support RD, including surrogate marker identification, disease progression assessment, and efficacy evaluation in preclinical and clinical phases.
Who are the top competitors of ImmunoSCAPE?
ImmunoSCAPE's top competitors include Quantumcyte, Reaction Biology and PhenoVista.
What products or services does ImmunoSCAPE offer?
ImmunoSCAPE offers TCR-based Therapeutics, Deep Immunomics Platform, and Machine Learning Platform.
Who are ImmunoSCAPE's investors?
ImmunoSCAPE has 4 investors. Key investors include Amgen, Anzu Partners, EDBI, and UT-EC Japan.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.